To this end, we are conducting an NCI-sponsored ECOG-ACRIN clinical trial, EAZ171 (NCT04001829), to prospectively test whether breast cancer patients of African descent with germline SBF2 mutations do indeed have higher rates of TIPN. Here, SBF2 is linked to breast cancer.